Calmark Sweden is granted two new patents
Calmark Sweden AB has been granted two new patents, one concerning the technical construction of the single-use item and one concerning the method of reading bilirubin. These will be published in the Swedish Patent Gazette No. 2020/39, on 2020-09-22. The patents are numbered 543 001 and 543 002.
As previously announced, Calmark filed two more patent applications to the Swedish Intellectual Property Office (PRV) on July 10, 2018. One patent relates to the unique technical solution for the single-use item, which ensures that exact blood volume and measurement time are achieved independently of the user. The second is a method patent concerning the reading of the biomarker bilirubin using a colorimetric analysis method.
These patents have now been granted by PRV and provide protection on the Swedish market until July 2038. The patents have been developed in close cooperation with the company’s patent agent Hynell Patenttjänst AB.
Patent protection in more markets will now be filed.
Including the new patents, Calmark owns fifteen patents and five design protections for the reader and the single-use item.
"Today's announcement is gratifying," says Anna Söderlund, CEO of Calmark. “For Calmark, it is strategically important to have broad patent protection for the company's technologies and methods. We are continuously trying to patent our innovations. Good IP protection will strengthen us in the global market launch.”
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a reader and single-use products. The first tests are being launched in 2020. WHO expects 1.5 billion children to be born worldwide prior to 2030. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer decision-making support, which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.